Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
Retrieved on:
Thursday, February 16, 2023
Well, MBA, NASH, Toxicity, DNA, Viral, Hepatitis, PD, Therapy, Taipei International Convention Center, Treatment, PD-1, PD-L1, Thyroid, Safety, Toxicology, Hyperlipidemia, Patient, Small RNA, RNA, Fatty liver disease, HV, Doctor of Philosophy, Hepatocyte, HBV, Hepatitis B, Tolerability, Thyroid hormones, Novel, Pharmacology, CHB, SAN, Jacob Aligo, Conference, CccDNA, Vaccine, Pharmaceutical industry, Dietary supplement, HBsAg, Single, Pharmacokinetics, Liver
Posters will be available for viewing throughout the conference for attendees and are also available on Aligos’ corporate website’s Scientific Presentations & Conferences page.
Key Points:
- Posters will be available for viewing throughout the conference for attendees and are also available on Aligos’ corporate website’s Scientific Presentations & Conferences page.
- HBsAg declines as high as 0.78 log10 IU/mL were seen in subjects achieving drug exposures corresponding to 300 mg for 28 days.
- Additionally, subjects achieving drug exposures corresponding to 300 mg for 28 days demonstrated HBsAg declines up to 0.78 log10 IU/mL.
- ALG-093702’s potential to mitigate immune-related systemic toxicity makes it a candidate for use in CHB or other indications in the liver.